Mehlhorn U, Bloch W, Krahwinkel A, LaRose K, Geissler H J, Hekmat K, Addicks K, de Vivie E R
Department of Cardiothoracic Surgery, University of Cologne, Joseph-Stelzmann Strasse 9, Cologne, Germany.
Eur J Cardiothorac Surg. 2000 Mar;17(3):305-11. doi: 10.1016/s1010-7940(00)00337-7.
The role of nitric oxide (NO) in myocardial ischemia/reperfusion is controversial. While some studies have shown cardioprotective effects of NO, others suggested that increased myocardial NO release secondary to ischemia may contribute to reperfusion injury. However, the impact of cardioplegia-induced myocardial ischemia/reperfusion on the activity of the NO-producing enzyme constitutive NO-synthase (cNOS or NOS-III) has not been investigated.
Twenty elective CABG patients were randomized to receive myocardial protection using either intermittent cold blood cardioplegia with 'hot-shot' (CBC; n=10) or continuous warm blood enriched with the ultra-fast-acting beta-blocker esmolol (WBE; n=10). We collected transmural LV biopsies prior to cardiopulmonary bypass (CPB), at the end of the cross-clamp period, and at the end of CPB. Specimen were subjected to immunocytochemical staining against myocardial NOS-III and cGMP using polyclonal antibodies. NOS-III activity was determined using TV-densitometry (gray units) and cGMP content using a semiquantitative score. Global myocardial metabolism was assessed by arterio-coronary sinus lactate concentration difference (a-csD(LAC)). For LV function determination we measured the fractional area of contraction (FAC) using TEE.
In CBC hearts a-csD(LAC) was significantly decreased following cross-clamp removal as compared to pre-CPB indicating global ischemia during cross-clamp. In contrast, a-csD(LAC) was unchanged in WBE hearts indicating absence of relevant ischemia in this group. In CBC hearts NOS-III activity did not change from pre-CPB (35.6+/-11.1 U) to the end of the cross-clamp period (38. 0+/-8.1 U; P=0.2), but increased significantly to 48.5+/-12.1 U at the end of CPB following initial warm blood reperfusion (P=0.026). In WBE hearts NOS-III activity remained unchanged throughout (29. 2+/-10.8, 35.1+/-11.8, and 32.2+/-14.7 U, respectively; 0.3). At the end of CPB, nine CBC hearts, but only one WBE heart showed increased cGMP content (P=0.002). Compared to pre-CPB, FAC in the CBC group was 109+/-25% following weaning off CPB (P=0.26), but was slightly decreased to 87+/-22% at 4 h post-CPB (P=0.03). In the WBE group FAC remained unchanged compared to pre-CPB throughout (103+/-21 and 96+/-37%, respectively; 0.5).
Our data show that global myocardial ischemia and reperfusion induced by CBC is associated with myocardial NOS-III activation and increased cGMP content suggesting increased NO release. In contrast, avoidance of ischemia by use of WBE prevented NOS-III and c-GMP increase. As LV function was decreased at 4 h post-CPB in the CBC group, these data suggest that increased NO release secondary to NOS-III activation may have contributed to ischemia-reperfusion injury as has been shown experimentally.
一氧化氮(NO)在心肌缺血/再灌注中的作用存在争议。一些研究显示NO具有心脏保护作用,而另一些研究则表明,缺血继发的心肌NO释放增加可能导致再灌注损伤。然而,停搏液诱导的心肌缺血/再灌注对产生NO的酶即组成型一氧化氮合酶(cNOS或NOS-III)活性的影响尚未得到研究。
20例择期冠状动脉旁路移植术(CABG)患者被随机分为两组,分别接受使用“热射”间歇性冷血停搏液(CBC;n = 10)或含超短效β受体阻滞剂艾司洛尔的持续温血停搏液(WBE;n = 10)进行心肌保护。我们在体外循环(CPB)前、阻断主动脉期间结束时以及CPB结束时采集左心室透壁活检组织。标本使用多克隆抗体进行心肌NOS-III和环磷酸鸟苷(cGMP)的免疫细胞化学染色。使用电视密度测定法(灰度单位)测定NOS-III活性,使用半定量评分法测定cGMP含量。通过动脉-冠状窦乳酸浓度差(a-csD(LAC))评估整体心肌代谢。为了测定左心室功能,我们使用经食管超声心动图(TEE)测量收缩分数面积(FAC)。
与CPB前相比,CBC组心脏在松开主动脉阻断钳后a-csD(LAC)显著降低,表明在阻断主动脉期间出现整体缺血。相比之下,WBE组心脏的a-csD(LAC)没有变化,表明该组不存在相关缺血。在CBC组心脏中,NOS-III活性从CPB前的(35.6±11.1 U)到阻断主动脉期间结束时(38.0±8.1 U;P = 0.2)没有变化,但在初始温血再灌注后CPB结束时显著增加至48.5±12.1 U(P = 0.026)。在WBE组心脏中,NOS-III活性在整个过程中保持不变(分别为29.2±10.8、35.1±11.8和32.2±14.7 U;P = 0.3)。在CPB结束时,9例CBC组心脏,但只有1例WBE组心脏显示cGMP含量增加(P = 0.002)。与CPB前相比,CBC组在脱离CPB后FAC为109±25%(P = 0.26),但在CPB后4小时略有下降至87±22%(P = 0.03)。在WBE组中,FAC与CPB前相比在整个过程中保持不变(分别为103±21和96±37%;P = 0.5)。
我们的数据表明,CBC诱导的整体心肌缺血和再灌注与心肌NOS-III激活和cGMP含量增加有关,提示NO释放增加。相比之下,使用WBE避免缺血可防止NOS-III和cGMP增加。由于CBC组在CPB后4小时左心室功能下降,这些数据表明,如实验所示,NOS-III激活继发的NO释放增加可能导致了缺血-再灌注损伤。